Neuro-Oncology: Current Concepts and Emerging Therapeutics.
作者信息
Nabors Burt, Laterra John
机构信息
University of Alabama School of Medicine, Birmingham, AL, USA.
Johns Hopkins School of Medicine, Baltimore, MD, USA.
出版信息
Neurotherapeutics. 2017 Apr;14(2):253-255. doi: 10.1007/s13311-017-0529-8.
Abstract
摘要
相似文献
1
Neuro-Oncology: Current Concepts and Emerging Therapeutics.神经肿瘤学：当前概念与新兴疗法
Neurotherapeutics. 2017 Apr;14(2):253-255. doi: 10.1007/s13311-017-0529-8.
2
Applications of artificial intelligence in neuro-oncology.人工智能在神经肿瘤学中的应用。
Curr Opin Neurol. 2019 Dec;32(6):850-856. doi: 10.1097/WCO.0000000000000761.
3
Neuro-oncology: continuing multidisciplinary progress.神经肿瘤学：多学科持续进展。
Lancet Neurol. 2011 Jan;10(1):18-20. doi: 10.1016/S1474-4422(10)70302-1.
4
Neuro-oncology: new insights and advances in treatment.神经肿瘤学：治疗方面的新见解与进展
Lancet Neurol. 2008 Jan;7(1):14-6. doi: 10.1016/S1474-4422(07)70305-8.
5
The position of the neurologist in neuro-oncology.神经科医生在神经肿瘤学中的地位。
Eur J Neurol. 2002 May;9(3):201-5. doi: 10.1046/j.1468-1331.2002.00411.x.
6
Neuro-oncology: setting new standards of management.神经肿瘤学：树立管理新标准。
Lancet Neurol. 2006 Jan;5(1):8-9. doi: 10.1016/S1474-4422(05)70260-X.
7
The future of neuro-oncology.神经肿瘤学的未来。
Acta Neurochir (Wien). 2009 Nov;151(11):1343-8. doi: 10.1007/s00701-009-0471-6. Epub 2009 Jul 29.
8
The future of neuro-oncology.神经肿瘤学的未来。
Crit Care Nurs Clin North Am. 1995 Mar;7(1):179-83.
9
Anatomic, physiologic and metabolic imaging in neuro-oncology.神经肿瘤学中的解剖、生理和代谢成像。
Cancer Treat Res. 2008;143:3-42. doi: 10.1007/978-0-387-75587-8_1.
10
Neuro-oncology and palliative care: a challenging interface.神经肿瘤学与姑息治疗：一个具有挑战性的交叉领域。
Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv3-7. doi: 10.1093/neuonc/nos209.
引用本文的文献
1
Therapeutic Options in Neuro-Oncology.神经肿瘤学的治疗选择。
Int J Mol Sci. 2022 May 11;23(10):5351. doi: 10.3390/ijms23105351.
本文引用的文献
1
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.达拉非尼用于BRAFV600突变的间变性多形性黄色星形细胞瘤
CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.
2
Bevacizumab for newly diagnosed glioblastoma.贝伐单抗用于新诊断的胶质母细胞瘤。
N Engl J Med. 2014 May 22;370(21):2048-9. doi: 10.1056/NEJMc1403303.
3
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
4
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.三期临床试验：放化疗治疗间变性少突胶质细胞瘤：RTOG9402 的长期结果。
J Clin Oncol. 2013 Jan 20;31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub 2012 Oct 15.
5
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.替莫唑胺辅助治疗新诊断的间变性少突胶质细胞瘤：欧洲癌症研究与治疗组织脑肿瘤研究组 26951 号研究的长期随访。
J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.
6
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.美国食品和药物管理局药物审批摘要：贝伐单抗（阿瓦斯汀）治疗复发性多形性胶质母细胞瘤。
Oncologist. 2009 Nov;14(11):1131-8. doi: 10.1634/theoncologist.2009-0121. Epub 2009 Nov 6.
7
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究：EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
8
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.全面的基因组特征分析确定了人类胶质母细胞瘤的基因和核心通路。
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
9
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.放疗联合同步及辅助替莫唑胺治疗胶质母细胞瘤
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
Zotero 插件